Low human papillomavirus vaccine uptake among women engaged in HIV care in Ontario, Canada.


Journal

Preventive medicine
ISSN: 1096-0260
Titre abrégé: Prev Med
Pays: United States
ID NLM: 0322116

Informations de publication

Date de publication:
11 2022
Historique:
received: 04 05 2022
revised: 08 08 2022
accepted: 02 09 2022
pubmed: 9 9 2022
medline: 23 11 2022
entrez: 8 9 2022
Statut: ppublish

Résumé

Women living with HIV are at higher risk for human papillomavirus (HPV)-related dysplasia and cancers and thus are prioritized for HPV vaccination. We measured HPV vaccine uptake among women engaged in HIV care in Ontario, Canada, and identified socio-demographic, behavioural, and clinical characteristics associated with HPV vaccination. During annual interviews from 2017 to 2020, women participating in a multi-site, clinical HIV cohort responded to a cross-sectional survey on HPV vaccine knowledge and receipt. We used logistic regression to derive age-adjusted odds ratios and 95% confidence intervals (CI) for factors associated with self-reported vaccine initiation (≥1 dose) or series completion (3 doses). Among 591 women (median age = 48 years; interquartile range = 40-56 years), 13.2% (95%CI = 10.5-15.9%) had received ≥1 dose. Of those vaccinated, 64.6% had received 3 doses. Vaccine initiation (≥1 dose) was significantly higher among women aged 20-29 years at 31.0% but fell to 13.9% in those aged 30-49 years and < 10% in those aged ≥50 years. After age adjustment, vaccine initiation was significantly associated with being employed (vs. unemployed but seeking work), income $40,000-$59,999 (vs. <$20,000), being married/common-law (vs. single), living with children, immigrating to Canada >5 years ago (vs. immigrating ≤5 years ago), never smoking (vs. currently smoking), and being in HIV care longer (per 10 years). Similar factors were identified for series completion (3 doses). HPV vaccine uptake remains low among women living with HIV in our cohort despite regular engagement in care. Recommendations for improving uptake include education of healthcare providers, targeted community outreach, and public funding of HPV vaccination.

Identifiants

pubmed: 36075492
pii: S0091-7435(22)00295-X
doi: 10.1016/j.ypmed.2022.107246
pii:
doi:

Substances chimiques

Papillomavirus Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

107246

Subventions

Organisme : CIHR
ID : 148432
Pays : Canada
Organisme : CIHR
ID : 415141
Pays : Canada

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Catharine Chambers (C)

University of Toronto, Toronto, Canada; St. Michael's Hospital, Unity Health Toronto, Toronto, Canada.

Jennifer Gillis (J)

University of British Columbia, Vancouver, Canada.

Joanne Lindsay (J)

St. Michael's Hospital, Unity Health Toronto, Toronto, Canada.

Anita C Benoit (AC)

University of Toronto, Toronto, Canada; Women's College Research Institute, Toronto, Canada.

Claire E Kendall (CE)

Bruyère Research Institute, Ottawa, Canada; Faculty of Medicine, University of Ottawa, Ottawa, Canada; ICES (formerly Institute for Clinical Evaluative Sciences), Toronto, Canada.

Abigail Kroch (A)

University of Toronto, Toronto, Canada; Ontario HIV Treatment Network, Toronto, Canada; Public Health Ontario, Toronto, Canada.

Ramandip Grewal (R)

St. Michael's Hospital, Unity Health Toronto, Toronto, Canada; Public Health Ontario, Toronto, Canada.

Mona Loutfy (M)

Women's College Research Institute, Toronto, Canada.

Ashley Mah (A)

St. Michael's Hospital, Unity Health Toronto, Toronto, Canada.

Kristen O'Brien (K)

Ontario HIV Treatment Network, Toronto, Canada.

Gina Ogilvie (G)

University of British Columbia, Vancouver, Canada.

Janet Raboud (J)

University of Toronto, Toronto, Canada; Toronto General Hospital Research Institute, University Health Network, Toronto, Canada.

Anita Rachlis (A)

Sunnybrook Health Sciences Centre, Toronto, Canada.

Beth Rachlis (B)

University of Toronto, Toronto, Canada; ICES (formerly Institute for Clinical Evaluative Sciences), Toronto, Canada.

Anna Yeung (A)

St. Michael's Hospital, Unity Health Toronto, Toronto, Canada.

Mark H Yudin (MH)

St. Michael's Hospital, Unity Health Toronto, Toronto, Canada.

Ann N Burchell (AN)

University of Toronto, Toronto, Canada; St. Michael's Hospital, Unity Health Toronto, Toronto, Canada. Electronic address: Ann.Burchell@unityhealth.to.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH